-
Je něco špatně v tomto záznamu ?
Dermatan sulfate released after injury is a potent promoter of fibroblast growth factor-2 function
SF. Penc, B. Pomahac, T. Winkler, RA. Dorschner, E. Eriksson, M. Herndon, RL. Gallo,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
NLK
Freely Accessible Science Journals
od 1905 do Před 1 rokem
Open Access Digital Library
od 1905-10-01
Open Access Digital Library
od 1905-10-01
ROAD: Directory of Open Access Scholarly Resources
od 1905
PubMed
9774430
Knihovny.cz E-zdroje
- MeSH
- buněčné dělení účinky léků MeSH
- dermatansulfát izolace a purifikace farmakologie MeSH
- fibroblastový růstový faktor 2 farmakologie MeSH
- hojení ran * MeSH
- krk chirurgie MeSH
- lidé MeSH
- mastektomie MeSH
- penetrující rány MeSH
- tělesné tekutiny chemie MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
Proteoglycans have been shown in vitro to bind multiple components of the cellular microenvironment that function during wound healing. To study the composition and function of these molecules when derived from an in vivo source, soluble proteoglycans released into human wound fluid were characterized and evaluated for influence on fibroblast growth factor-2 activity. Immunoblot analysis of wound fluid revealed the presence of syndecan-1, syndecan-4, glypican, decorin, perlecan, and versican. Sulfated glycosaminoglycan concentrations ranged from 15 to 65 microgram/ml, and treatment with chondroitinase B showed that a large proportion of the glycosaminoglycan was dermatan sulfate. The total glycosaminoglycan mixture present in wound fluid supported the ability of fibroblast growth factor-2 to signal cell proliferation. Dermatan sulfate, and not heparan sulfate, was the major contributor to this activity, and dermatan sulfate bound FGF-2 with Kd = 2.48 microM. These data demonstrate that proteoglycans released during wound repair are functionally active and provide the first evidence that dermatan sulfate is a potent mediator of fibroblast growth factor-2 responsiveness.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15012647
- 003
- CZ-PrNML
- 005
- 20151022094452.0
- 007
- ta
- 008
- 150409s1998 xxu f 000 0|eng||
- 009
- AR
- 035 __
- $a (PubMed)9774430
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Penc, S F $u Division of Developmental and Newborn Biology, Boston's Children's Hospital, Boston, Massachusetts 02115, USA.
- 245 10
- $a Dermatan sulfate released after injury is a potent promoter of fibroblast growth factor-2 function / $c SF. Penc, B. Pomahac, T. Winkler, RA. Dorschner, E. Eriksson, M. Herndon, RL. Gallo,
- 520 9_
- $a Proteoglycans have been shown in vitro to bind multiple components of the cellular microenvironment that function during wound healing. To study the composition and function of these molecules when derived from an in vivo source, soluble proteoglycans released into human wound fluid were characterized and evaluated for influence on fibroblast growth factor-2 activity. Immunoblot analysis of wound fluid revealed the presence of syndecan-1, syndecan-4, glypican, decorin, perlecan, and versican. Sulfated glycosaminoglycan concentrations ranged from 15 to 65 microgram/ml, and treatment with chondroitinase B showed that a large proportion of the glycosaminoglycan was dermatan sulfate. The total glycosaminoglycan mixture present in wound fluid supported the ability of fibroblast growth factor-2 to signal cell proliferation. Dermatan sulfate, and not heparan sulfate, was the major contributor to this activity, and dermatan sulfate bound FGF-2 with Kd = 2.48 microM. These data demonstrate that proteoglycans released during wound repair are functionally active and provide the first evidence that dermatan sulfate is a potent mediator of fibroblast growth factor-2 responsiveness.
- 650 _2
- $a tělesné tekutiny $x chemie $7 D001826
- 650 _2
- $a buněčné dělení $x účinky léků $7 D002455
- 650 _2
- $a dermatansulfát $x izolace a purifikace $x farmakologie $7 D003871
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a fibroblastový růstový faktor 2 $x farmakologie $7 D016222
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mastektomie $7 D008408
- 650 _2
- $a krk $x chirurgie $7 D009333
- 650 12
- $a hojení ran $7 D014945
- 650 _2
- $a penetrující rány $7 D014950
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Pomahač, Bohdan, $d 1971- $7 xx0117402
- 700 1_
- $a Winkler, T
- 700 1_
- $a Dorschner, R A
- 700 1_
- $a Eriksson, E
- 700 1_
- $a Herndon, M
- 700 1_
- $a Gallo, R L
- 773 0_
- $w MED00002546 $t The Journal of biological chemistry $x 0021-9258 $g Roč. 273, č. 43 (1998), s. 28116-21
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/9774430 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20150409 $b ABA008
- 991 __
- $a 20151022094647 $b ABA008
- 999 __
- $a ok $b bmc $g 1070818 $s 895506
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 1998 $b 273 $c 43 $d 28116-21 $i 0021-9258 $m The Journal of biological chemistry $n J Biol Chem $x MED00002546
- LZP __
- $a Pubmed-20150409